Lineage Cell Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
LCTX$1.04-3.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STAT EMENTS OF CASH FLOWS
| Year Ended December 31, | ||||
|---|---|---|---|---|
| 2023 · 2022 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss attributable to Lineage Cell Therapeutics, Inc. | $(21,486) | $(26,273) | ||
| Net income (loss) allocable to noncontrolling interest | 7 | (80) | ||
| Adjustments to reconcile net loss attributable to Lineage Cell Therapeutics, Inc. to net cash (used in) provided by operating activities: | ||||
| Loss on marketable equity securities, net | 176 | 2,194 | ||
| Accretion of income on marketable debt securities | (679) | (501) | ||
| Depreciation expense, including amortization of leasehold improvements | 562 | 582 | ||
| Change in right-of-use assets and liabilities | 91 | (35) | ||
| Amortization of intangible assets | 130 | 145 | ||
| Stock-based compensation | 4,640 | 4,287 | ||
| Gain on revaluation of warrant liability | (2) | (225) | ||
| Deferred income tax benefit | (1,803) | — | ||
| Foreign currency remeasurement and other loss | 602 | 2,272 | ||
| Gain on sale of assets | — | (11) | ||
| Changes in operating assets and liabilities: | ||||
| Accounts receivable, net (Note 3) | (446) | 50,314 | ||
| Prepaid expenses and other current assets | (418) | 446 | ||
| Accounts payable and accrued liabilities (Note 7) | (2,295) | (18,702) | ||
| Deferred revenue (Note 3) | (7,645) | (13,354) | ||
| Net cash (used in) provided by operating activities | (28,566) | 1,059 | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Proceeds from the sale of marketable equity securities | 196 | — | ||
| Purchases of marketable debt securities | (16,403) | (53,412) | ||
| Maturities of marketable debt securities | 63,330 | 7,666 | ||
| Purchase of equipment | (674) | (413) | ||
| Net cash provided by (used in) investing activities | 46,449 | (46,159) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from employee options exercised | 88 | 648 | ||
| Common shares received and retired for employee taxes paid | (37) | (17) | ||
| Proceeds from exercise of subsidiary warrants, net | — | 991 | ||
| Proceeds from sale of common shares | 6,625 | 148 | ||
| Payments for offering costs | (199) | (106) | ||
| Repayment of finance lease liabilities | (54) | (32) | ||
| Net cash provided by financing activities | 6,423 | 1,632 | ||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (250) | (873) | ||
| NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH | 24,056 | (44,341) | ||
| CASH, CASH EQUIVALENTS AND RESTRICTED CASH: | ||||
| At beginning of the period | 11,936 | 56,277 | ||
| At end of the period | $35,992 | $11,936 | ||
| SUPPLEMENTAL DISCLOSURES | ||||
| Cash paid for interest | $10 | $13 | ||
| SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING AND INVESTING ACTIVITIES: | ||||
| Property and equipment expenditures in accounts payable | $8 | $28 | ||
| Amortization of financing costs | $22 | $ | - | |
| Receivable from exercise of stock options | $ | - | $32 | |
| Reconciliation of cash, cash equivalents and restricted cash, end of period: | ||||
| Cash and cash equivalents | $35,442 | $11,355 | ||
| Restricted cash included in deposits and other long-term assets (see Note 14 (Commitments and Contingencies)) | 550 | 581 | ||
| Total cash, cash equivalents, and restricted cash | $35,992 | $11,936 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.